Published in Clin Cancer Res on December 09, 2015
IL-17 and Th17 Cells. Annu Rev Immunol (2009) 23.02
IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature (2007) 16.59
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol (2003) 5.36
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol (2002) 3.63
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med (2011) 3.12
Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol (2006) 2.71
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest (2001) 2.11
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity (2014) 1.87
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol (2013) 1.67
Pathogen-Specific T Cell Polyfunctionality Is a Correlate of T Cell Efficacy and Immune Protection. PLoS One (2015) 1.55
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer (2013) 1.50
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res (2004) 1.49
IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol (2012) 1.44
Regulation of innate CD8+ T-cell activation mediated by cytokines. Proc Natl Acad Sci U S A (2012) 1.38
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood (2010) 1.29
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res (2008) 1.24
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood (2010) 1.23
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res (2006) 1.22
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy (2009) 1.21
Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res (2011) 1.08
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res (2012) 1.05
Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood (2012) 1.02
Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res (2013) 1.02
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res (2007) 1.01
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res (2014) 1.01
IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens. J Immunol (2013) 0.99
Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol (1989) 0.98
Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women. Cancer Res (2012) 0.98
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. Discov Med (2014) 0.93
A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila) (2013) 0.93
IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol (2004) 0.88
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. Cancer Immunol Immunother (2013) 0.84
RORγt(+) hematopoietic cells are necessary for tumor cell proliferation during colitis-associated tumorigenesis in mice. Eur J Immunol (2015) 0.80
An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis. Cancer Res (2015) 0.80
Donor-derived CD19 chimeric antigen receptor T cells. Curr Opin Hematol (2015) 0.77
Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation. J Virol (2014) 0.77
IL-4 enhances long-term survival of CD28-deficient T cells. J Immunol (1998) 0.76
Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer. Mol Carcinog (2015) 0.79
Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo. Clin Cancer Res (2016) 0.75